• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Reata Pharmaceuticals Inc. (Amendment)

    5/15/23 4:22:34 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RETA alert in real time by email
    SC 13G/A 1 reta-sc13ga_051223.htm AMENDMENT TO FORM SC 13G
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 2)

     
    Reata Pharmaceuticals Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    75615P103

    (CUSIP Number)

     

    May 12, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☒ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No . 75615P103   Page 2 of 7

     

    1

    NAME OF REPORTING PERSONS
    First Light Asset Management, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

    46-3521994

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    1,290,193

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,290,193

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,290,193

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.91%

     
    12

    TYPE OF REPORTING PERSON

    IA

     
             

     

     
     

     

     

    CUSIP No . 75615P103   Page 3 of 7  
             
    1

    NAME OF REPORTING PERSONS
    Mathew P. Arens

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    21,054

     
    6

    SHARED VOTING POWER

    1,298,433

     
    7

    SOLE DISPOSITIVE POWER

    21,054

     
    8

    SHARED DISPOSITIVE POWER

    1,298,433

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,319,487

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.00%

     
    12

    TYPE OF REPORTING PERSON

    IN

     
                             

     

     

     
     

     

    CUSIP No. 75615P103   Page 4 of 7

     

    Item 1(a).   Name of Issuer:
        Reata Pharmaceuticals, Inc.
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
        5320 Legacy Drive, Plano, TX 75024
         
    Item 2(a).   Name of Person Filing:
       

    This Schedule 13G is being jointly filed by the following:

     

    First Light Asset Management, LLC (the “Manager”)

    Mathew P. Arens (“Mr. Arens”)

       

     

    The Manager may be deemed to be the beneficial owner of 1,290,193 of the Issuer’s shares of common stock (the “Shares”). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. Mr. Arens also directly holds 21,054 Shares in an individual capacity with sole control and 8,240 Shares held in a joint account over which he shares control. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act.

     

    The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
       

    Each of the reporting persons identified in Item 2(a) has its principal business office at:

     

    3300 Edinborough Way, Suite 201, Edina, MN 55435

         
    Item 2(c).   Citizenship:
       

    First Light Asset Management, LLC – Delaware limited liability company

    Mathew P. Arens – United States citizen

         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.01 par value
         
    Item 2(e).   CUSIP Number:
         75615P103
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     
     

     

     

    CUSIP No . 75615P103   Page 5 of 7
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☒ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
       

    First Light Asset Management, LLC – 1,290,193

    Mathew P. Arens – 1,319,487

         
      (b) Percent of class:
       

    First Light Asset Management, LLC – 3.91%

    Mathew P. Arens – 4.00%

     
         
      (c) Number of shares as to which such person has:
         
        (i) Sole power to vote or to direct the vote
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 21,054

           
        (ii) Shared power to vote or to direct the vote
         

    First Light Asset Management, LLC – 1,290,193

    Mathew P. Arens – 1,298,433

           
        (iii) Sole power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 21,054

           
        (iv) Shared power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 1,290,193

    Mathew P. Arens – 1,298,433

                 

     

     

     
     

     

    CUSIP No . 75615P103   Page 6 of 7

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

         
     

    FIRST LIGHT ASSET MANAGEMENT, LLC

     

    Date: May 15, 2023

     
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
     

     

    Date: May 15, 2023

     
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  
         

     

     

     
     

     


    CUSIP No .
    75615P103   Page 7 of 7

     

    Exhibit A

    JOINT FILING AGREEMENT

     

     

    The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Reata Pharmaceuticals, Inc, dated as of May 15, 2023, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

         
     

    FIRST LIGHT ASSET MANAGEMENT, LLC

     
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  

     

     

    Get the next $RETA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RETA

    DatePrice TargetRatingAnalyst
    7/6/2023$140.00Outperform
    TD Cowen
    6/12/2023$80.00 → $115.00Market Perform → Outperform
    SVB Securities
    10/19/2022$75.00Buy
    Guggenheim
    3/24/2022$91.00Buy
    Goldman
    3/1/2022$39.00 → $34.00Neutral
    Goldman Sachs
    12/9/2021$39.00Buy → Neutral
    Goldman Sachs
    12/9/2021$110.00 → $37.00Outperform → Neutral
    Robert W. Baird
    12/9/2021$112.00 → $68.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RETA
    Financials

    Live finance-specific insights

    See more
    • Biogen Completes Acquisition of Reata Pharmaceuticals

      Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of

      9/26/23 8:59:54 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biogen to Acquire Reata Pharmaceuticals

      SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia   Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a

      7/28/23 7:05:44 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

      SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through the End of 2026 Focus on Neurology Pipeline; Announced Discontinuation of Bardoxolone CKD Programs Conference Call with Management on May 10, 2023, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter

      5/10/23 6:40:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Reata Pharmaceuticals with a new price target

      TD Cowen initiated coverage of Reata Pharmaceuticals with a rating of Outperform and set a new price target of $140.00

      7/6/23 7:38:38 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Pharmaceuticals upgraded by SVB Securities with a new price target

      SVB Securities upgraded Reata Pharmaceuticals from Market Perform to Outperform and set a new price target of $115.00 from $80.00 previously

      6/12/23 7:22:49 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Reata Pharmaceuticals with a new price target

      Guggenheim initiated coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $75.00

      10/19/22 7:56:15 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/28/23 4:32:06 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcgaughy R Kent Jr returned 2,926,776 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/26/23 7:18:56 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wortley Michael D returned 49,701 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/26/23 4:30:47 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biogen Completes Acquisition of Reata Pharmaceuticals

      Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of

      9/26/23 8:59:54 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company's previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). Approximately 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders, voting as a single class, entitled to vote at the special meeting, voted to approve the Merger, which represen

      9/21/23 10:08:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

      NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo

      8/5/23 8:13:00 PM ET
      $EQRX
      $NEWR
      $RETA
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology

    $RETA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Reata Pharmaceuticals Inc.

      15-12G - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      10/6/23 4:07:57 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

      8-K - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      9/26/23 5:25:59 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Reata Pharmaceuticals Inc.

      POSASR - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      9/26/23 4:25:20 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Leadership Updates

    Live Leadership Updates

    See more
    • Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le

      6/13/23 6:45:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. "We are thrilled to welcome Dr. Ryder to Reata's board," said Warren Huff, Reata's Chief Executive Officer. "He is joining us at a critical point in Reata's development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia. His knowledge will be invaluable to help us achieve our mission in developing innovative therapies that change patients' lives for the bett

      7/11/22 6:45:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

      Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

      2/28/23 5:14:09 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/28/23 4:38:52 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/28/23 4:30:35 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/26/23 4:32:57 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care